Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock - Scorecard - MDSpire
Clinical Scorecard: Time-Dependent Cytokine Patterns During Microaxial Flow Pump Support in Cardiogenic Shock
At a Glance
Category
Detail
Condition
Cardiogenic shock (CS), an acute circulatory failure resulting from primary cardiac dysfunction.
Key Mechanisms
Myocardial ischemia and reperfusion can trigger sterile inflammation through damage-associated molecular patterns and innate immune pathways, with cytokines including IL-1β, IL-6, IL-8, and TNF-α.
Target Population
Adults with CS at SCAI stage C or above treated with an Impella microaxial flow pump; the study excluded support under 24 hours, concomitant VA-ECMO, Impella 5.5, and absent serial cytokine measurements.
Care Setting
Retrospective, single-center cohort at a German university hospital, involving patients receiving microaxial flow pump support for cardiogenic shock.
Key Highlights
The study evaluated serial IL-1β, IL-6, IL-8, and TNF-α measurements during microaxial flow pump support.
Measurements were scheduled at implantation and 24, 72, 120, and 168 hours; the 168-hour assessment was exploratory because fewer observations were available.
CRP and procalcitonin may rise in cardiogenic shock without microbiological evidence of infection, complicating interpretation of inflammatory findings.
Blood culture positivity was defined as identification of a microorganism in at least one blood culture; systematic infection adjudication was not consistently available.
The study examined associations between cytokine dynamics, infection markers, and clinical outcomes, including whether cytokines added prognostic information beyond hemodynamic indices.
Guideline-Based Recommendations
Diagnosis
The article describes cardiogenic shock as acute circulatory failure resulting from primary cardiac dysfunction and includes patients at SCAI stage C or above.
Management
The introduction states that current CS frameworks prioritize prompt clinical phenotyping and systematic escalation of temporary mechanical circulatory support.
The introduction notes randomized evidence supporting early ventricular unloading with a microaxial flow pump in selected patients; the study does not provide a new treatment recommendation.
Monitoring & Follow-up
The study collected cytokines at baseline and 24, 72, 120, and 168 hours, alongside CRP, procalcitonin, leukocyte count, VIS, SOFA score, and device variables.
The 168-hour cytokine time point was considered exploratory because relatively few observations were available.
Risks
The introduction associates IL-1β, IL-6, IL-8, and TNF-α with myocardial depression, vasoplegia, endothelial dysfunction, and microcirculatory impairment.
The introduction states that CRP and procalcitonin may rise in CS without microbiological evidence of infection.
The introduction notes that microaxial pump-related shear stress and hemolysis may influence inflammatory signaling.
Patient & Prescribing Data
Consecutive adults treated with an Impella microaxial pump for CS at SCAI stage C or above at one center between January 2021 and December 2023.
The study assessed cytokine trajectories during device support. It does not provide patient-level prescribing instructions or dosing recommendations.
Clinical Best Practices
The article notes that CRP and procalcitonin may rise in CS without microbiological evidence of infection; it does not establish a clinical interpretation protocol.
The study investigated longitudinal cytokine measurements alongside hemodynamic indices but does not establish a clinical protocol.
The article describes the 168-hour time point as exploratory because relatively few observations were available.
Related Resources & Content
SCAI SHOCK Stage Classification Expert Consensus Update, JACC, 2022 — A Review and Incorporation of Validation Studies
Journal of Cardiac Failure, year not provided — Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock—a Secondary Analysis of the DanGer Shock Trial
Journal of Cardiac Failure, year not provided — VA-ECMO Support in Cardiogenic Shock: A Post Hoc Analysis of cDPP3 Levels and Their Impact on Outcomes in the ADRECMO Cohort
Clinical Research in Cardiology — Timing of IABP initiation and its impact on outcomes in acute myocardial infarction with cardiogenic shock: insights from a bi-center retrospective study
Frontiers in Cardiovascular Medicine — Patterns of temporary mechanical circulatory support, escalation, de-escalation and outcomes in cardiogenic shock
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies
Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock—a Secondary Analysis of the DanGer Shock Trial
VA-ECMO Support in Cardiogenic Shock: A Post Hoc Analysis of cDPP3 Levels and Their Impact on Outcomes in the ADRECMO Cohort
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. | JACC
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock | New England Journal of Medicine
